Basic Information
TUBERCULIN PPD RT 23 AJV
INJECTION
Regulatory Information
SIN09944P
August 19, 1998
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
June 4, 2025
XV04CF01
Company Information
Active Ingredients
Strength: 0.4 mcg/ml
Detailed Information
Contraindications
**2.3 Contraindications** Tuberculin PPD RT 23 AJV should not be administered to: - Individuals known to be hypersensitive (Type I) to the active substance or any of the excipients of the medicinal product listed in section 1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. - Individuals who previously have experienced a severe local reaction to tuberculin products. A severe local reaction may include vesicles and ulceration at the injection site and skin necrosis at the centre of a widespread tuberculin reaction. The necrosis will generally disappear after a few days.
Indication Information
**2.1 Therapeutic indications** Tuberculin PPD RT 23 AJV is used for Mantoux tuberculin skin testing to diagnose if an individual has ever been infected with _Mycobacterium tuberculosis_. Some countries also recommend Mantoux tuberculin skin testing in conjunction with BCG vaccination, either to ensure that only tuberculin-negative individuals are vaccinated or as a post-vaccination test. Tuberculin PPD RT 23 AJV can be used in all age groups. This medicinal product is for diagnostic use only.